Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The European Society of Cardiology (ESC) Congress will be held in Munich, Germany, from August 28-31 2026. This meeting will bring together leading experts from around the world to discuss the latest advances and emerging research in the field of cardiology.

ESC 2026

ESC Congress 2026
28–31 August 2026 | Munich, Germany

ESC 2026

ESC Congress 2026
28–31 August 2026 | Munich, Germany
The European Society of Cardiology (ESC) Congress will be held in Munich, Germany, from August 28-31 2026. This meeting will bring together leading experts from around the world to discuss the latest advances and emerging research in the field of cardiology.
Comparing treatment strategies for ATTR-CM across clinical outcomes: insights from a meta-analysis 2:21
Comparing treatment strategies for ATTR-CM across clinical outcomes: insights from a meta-analysis
Adolfo Calderón Fernández • 29 Aug 2026
Transitioning anselamimab into clinical practice: key challenges and opportunities 1:00
Transitioning anselamimab into clinical practice: key challenges and opportunities
Xiaowen Wang • 30 Aug 2026
Emerging therapeutic strategies and clinical trials in ATTR-CM 1:32
Emerging therapeutic strategies and clinical trials in ATTR-CM
Ronald Witteles • 29 Aug 2026
Individualizing treatment strategies in cardiac amyloidosis: insights from a network meta-analysis 0:58
Individualizing treatment strategies in cardiac amyloidosis: insights from a network meta-analysis
Adolfo Calderón Fernández • 29 Aug 2026
Heterogeneity in cardiac amyloidosis care across Europe: insights from a KOL survey 2:46
Heterogeneity in cardiac amyloidosis care across Europe: insights from a KOL survey
Luuk Kieviet • 30 Aug 2026
Updated recommendations for ATTR-CM: treatment guidelines and monitoring disease progression 2:20
Updated recommendations for ATTR-CM: treatment guidelines and monitoring disease progression
Ronald Witteles • 29 Aug 2026
Common pitfalls in the diagnosis and management of ATTR-CM and how to overcome them 4:55
Common pitfalls in the diagnosis and management of ATTR-CM and how to overcome them
Ronald Witteles • 29 Aug 2026
Cardiac amyloidosis care across Europe: areas of greatest variation in diagnosis and management 1:24
Cardiac amyloidosis care across Europe: areas of greatest variation in diagnosis and management
Luuk Kieviet • 30 Aug 2026
Earlier detection of ATTR-CM: identifying patients before severe disease develops 1:39
Earlier detection of ATTR-CM: identifying patients before severe disease develops
Ilia Davarashvili • 29 Aug 2026
Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach 1:35
Managing patients flagged as high risk for ATTR-CM: insights into the multidisciplinary approach
Ilia Davarashvili • 29 Aug 2026
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR 2:03
Exploring an AI-guided screening approach for identifying patients at high risk of cardiac ATTR
Ilia Davarashvili • 29 Aug 2026
Addressing the risk of false positives with an AI-guided ATTR-CM screening model 1:05
Addressing the risk of false positives with an AI-guided ATTR-CM screening model
Ilia Davarashvili • 29 Aug 2026
Key priorities for achieving consistent cardiac amyloidosis care across Europe 2:00
Key priorities for achieving consistent cardiac amyloidosis care across Europe
Luuk Kieviet • 30 Aug 2026
Insights into the potential of CRISPR-based gene editing in ATTR-CM 4:07
Insights into the potential of CRISPR-based gene editing in ATTR-CM
Ronald Witteles • 29 Aug 2026
Emerging approaches being explored for AL amyloidosis 2:36
Emerging approaches being explored for AL amyloidosis
Ronald Witteles • 29 Aug 2026
Anselamimab in AL amyloidosis: efficacy and cardiac outcomes from the Phase III CARES trials 2:20
Anselamimab in AL amyloidosis: efficacy and cardiac outcomes from the Phase III CARES trials
Xiaowen Wang • 30 Aug 2026
The content of VJHemOnc is intended for healthcare professionals